Video Experimental Relacionado
Updated: Feb 10, 2026
23:06
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
19.6K
Tuberculosis extensamente resistente a los medicamentos en Togo: primeros casos reportados e implicaciones para el
Maïssala Zoutené1, Akouvi Mawussé Edjodjinam Ako1, Koffi Atsu Aziagbe1,2
1Department of Pulmonology, Sylvanus Olympio University Hospital, Lomé, Togo.
IJID regions
|February 9, 2026
Resumen
La tuberculosis extensamente resistente a los medicamentos (XDR-TB) presenta desafíos, pero es tratable. El diagnóstico precoz y las estrategias de tratamiento adaptadas son cruciales para obtener resultados exitosos en los casos de TB-XDR.
Área de la Ciencia:
- Pulmonología Pulmonología.
- Enfermedades infecciosas Enfermedades infecciosas.
- Salud Pública La salud pública.
Sus antecedentes:
- La tuberculosis extensamente resistente a los medicamentos (XDR-TB) representa una amenaza significativa para el control global de la tuberculosis.
- La gestión de la XDR-TB requiere una cuidadosa consideración de la historia clínica del paciente y la respuesta al tratamiento.
Objetivo del estudio:
- Para presentar una serie de casos que ilustran el curso clínico y el manejo de la tuberculosis extensamente resistente a los medicamentos (XDR-TB).
- Para resaltar los desafíos y los resultados exitosos en el tratamiento de pacientes con XDR-TB.
Principales métodos:
- Se realizó un estudio de serie de casos desde el 1 de enero de 2007 hasta el 31 de diciembre de 2024.
- Los datos se recopilaron de tres pacientes diagnosticados con XDR-TB en el Hospital Universitario Sylvanus Olympio.
Principales resultados:
- Caso 1: Un varón de 30 años logró la conversión de cultivo a los 3 meses, pero desarrolló pyopneumothorax. Caso 2: Un hombre de 51 años logró la conversión de cultivos 2 meses después de la modificación del tratamiento para la XDR-TB. Caso 3: Una mujer de 62 años con VIH y tratamiento previo de TB-MDR murió durante la terapia de TB-XDR.
Conclusiones:
- La tuberculosis extensamente resistente a los medicamentos (XDR-TB) es una enfermedad curable.
- Un diagnóstico rápido y preciso es esencial para seleccionar regímenes de tratamiento óptimos para la XDR-TB.
Videos de Conceptos Relacionados
01:29Pulmonary Tuberculosis I
998
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
998
01:28Pulmonary Tuberculosis II
1.5K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.5K
01:28Pulmonary Tuberculosis V
642
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
642
01:31Pulmonary Tuberculosis III
1.1K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
1.1K
01:26Pulmonary Tuberculosis IV
546
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
546
01:03Drug Control Governance: Regulatory Bodies and Their Impact
567
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
567